预约演示
Ariceum snaps up fellow European biotech Theragnostics to bolster radiopharma efforts
2023-06-01
临床1期并购寡核苷酸上市批准
Ariceum Therapeutics raised 25 million euros a year ago to advance its lead asset acquired from Ipsen.
Ariceum Therapeutics are all the rage in cancer drug development these days, and Germany-based AIpsenm Therapeutics doesn’t want to lose any ground.
The company is paying $2.5 million in cascancerBritish biotech Theragnostics. The acquisition bAriceum Therapeuticsle of assets, according to an announcement Thursday, for which Ariceum could end up handing out an additonal $41.5 million in milestone payments.
One of the newly acquired assets, THG-008, is a radiolabeled, cancer-imaging PARP inhibitor currently in a phase 1 trial at Memorial Sloan Kettering Hospital in New York. AriceumAriceumakes possession of THG-009, a radiopharmaceutical therapeutic aimed at PARP that’s being developed to treat patients with glioblastoma.
As well as taking on THG-008, the THG-008tion shores up AriceucanceragnosticsPARPorts in other ways, with the biotech now owMemorial Sloan Kettering Hospital which is usedAriceumntify kidney disorders. ThTHG-009will help bolster the company’s presence in tPARP.S., Ariceum CEO Manfred Rüdiger, Ph.D., said iglioblastomae.
Last but not least, ATHG-008s purchase includes TheragnoAriceumGa-68 kit technology IP that’s currently licensed to Novartis, one of the Big PharmNephroscanin radiopharmaceutical develkidney disordersAriceum
The deal adds depth Ariceumeum’s already establiTheragnosticsmall—radiopharma pipeline, led by satoreotide, a potentNovartisnostic and treatment for neuroendocrine cancers. The company closed a 25 million euro series A round a year ago after snapping up rights to satoreotide from Ipsen.
The purchase of TheragnAriceumis just the latest dealmaking on the radiopharmaceutical front, wsatoreotideminated headlines so far this year. Bicycleneuroendocrine cancers riding out front, inking two deals with Bayer and Novartis potentially worth up to $1.7 billsatoreotideIpsen
Newly launched bTheragnosticsing on the modality have also raked in cash. Convergent Therapeutics raised $90 million on the promise of its radBicycle Therapeutics May, and, a few weeks earlier, Abdera took flightBayer $142Novartis in financing.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。